Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and SBRT in Metastatic Melanoma
NCT02406183Phase 1Completed
- Start
- Mar 2015
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab in melanoma. Primary endpoint: Maximal tolerated dose at 2 years. Started Mar 2015; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02406183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406183.